State Key Laboratory for Animal Disease Control and Prevention, National African Swine Fever Para-reference Laboratory, National High Containment Facilities for Animal Diseases Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
Emerg Microbes Infect. 2024 Dec;13(1):2300464. doi: 10.1080/22221751.2023.2300464. Epub 2024 Jan 22.
Genetic changes have occurred in the genomes of prevalent African swine fever viruses (ASFVs) in the field in China, which may change their antigenic properties and result in immune escape. There is usually poor cross-protection between heterogonous isolates, and, therefore, it is important to test the cross-protection of the live attenuated ASFV vaccines against current prevalent heterogonous isolates. In this study, we evaluated the protective efficacy of the ASFV vaccine candidate HLJ/18-7GD against emerging isolates. HLJ/18-7GD provided protection against a highly virulent variant and a lower lethal isolate, both derived from genotype II Georgia07-like ASFV and isolated in 2020. HLJ/18-7GD vaccination prevented pigs from developing ASF-specific clinical signs and death, decreased viral shedding via the oral and rectal routes, and suppressed viral replication after challenges. However, HLJ/18-7GD vaccination did not provide solid cross-protection against genotype I NH/P68-like ASFV challenge in pigs. HLJ/18-7GD vaccination thus shows great promise as an alternative strategy for preventing and controlling genotype II ASFVs, but vaccines providing cross-protection against different ASFV genotypes may be needed in China.
在中国,流行的非洲猪瘟病毒(ASFV)的基因组发生了遗传变化,这可能改变其抗原特性并导致免疫逃逸。异源分离株之间通常交叉保护效果不佳,因此,测试活减毒 ASFV 疫苗对当前流行的异源分离株的交叉保护作用非常重要。在这项研究中,我们评估了 ASFV 疫苗候选株 HLJ/18-7GD 对新兴分离株的保护效力。HLJ/18-7GD 对高毒力变体和低致死性分离株均提供了保护,这两种分离株均源自基因型 II 格鲁吉亚 07 样 ASFV,于 2020 年分离得到。HLJ/18-7GD 接种可预防猪发生 ASF 特异性临床症状和死亡,通过口腔和直肠途径减少病毒脱落,并抑制接种后的病毒复制。然而,HLJ/18-7GD 接种不能为猪提供针对基因型 I NH/P68 样 ASFV 挑战的可靠交叉保护。因此,HLJ/18-7GD 接种作为预防和控制基因型 II ASFV 的替代策略具有很大的前景,但在中国可能需要提供针对不同 ASFV 基因型的交叉保护疫苗。